- FILTERS Advanced
- Product Type
- Clonality
- Application
- Species / Reactivity
- Source / Host
- Conjugation
- CE / IVD
- Clone ID
- Biosite Product Line
- Supplier
- EXCLUDE FILTERS
- Clonality
- Application
- Species / Reactivity
- Conjugation
- Clone ID
- Biosite Product Line
- Supplier
| Name | Art no | Species Reactivity | Application | Conjugation | Clone | Size | Price |
|---|---|---|---|---|---|---|---|
|
154-37164
|
|
ELISA, FC, IHC, IP, WB
|
|
IDEC-114 (Galiximab)
|
200 µg
|
||
|
154-37157
|
|
FC
|
|
10F381 (Rituximab)
|
200 µg
|
||
|
154-37158
|
|
FC, IP
|
|
hL22 (Epratuzumab)
|
200 µg
|
||
|
154-37169
|
|
FC
|
|
Daclizumab
|
200 µg
|
||
|
154-37170
|
|
FC, IF, IHC, WB
|
|
Basiliximab
|
200 µg
|
||
|
154-37159
|
|
FC, IF
|
|
hP67.6 (Gemtuzumab)
|
200 µg
|
||
|
154-37160
|
|
ELISA, FC, IHC
|
|
CE9.1 (Clenoliximab)
|
200 µg
|
||
|
154-37161
|
|
FC, IHC, WB
|
|
YNB46.1.8 (Campath-9H)
|
200 µg
|
||
|
154-37156
|
|
IF
|
|
IDEC-131 (Toralizumab)
|
200 µg
|
||
|
154-37162
|
|
FC, WB
|
|
hu5c8 (Ruplizumab)
|
200 µg
|
||
|
BT-4UI1HO-50
|
virus
|
ELISA
|
Unconjugated
|
|
50ul
|
||
|
BT-4UI1HO-100
|
virus
|
ELISA
|
Unconjugated
|
|
100ul
|
||
|
154-37167
|
|
FC, IHC
|
|
h-R3 (Nimotuzumab)
|
200 µg
|
||
|
154-37165
|
|
ELISA, FC, WB
|
|
2F8 (Zalutumumab; HuMax-EGFR)
|
200 µg
|
||
|
154-37166
|
|
FC
|
|
C225 (Cetuximab)
|
200 µg
|
||
|
Ab00230-35.0-BT
|
virus
|
IF, WB, Neutralization, ELISA, FC, IHC
|
Unconjugated
|
D1-4G2-4-15 (4G2)
|
1 mg
|
||
|
Ab00230-35.0
|
virus
|
IF, WB, Neutralization, ELISA, FC, IHC
|
Unconjugated
|
D1-4G2-4-15 (4G2)
|
100 µg
|
||
|
Ab00102-36.0-BT
|
|
WB
|
Unconjugated
|
4-4-20 (enhanced)
|
1 mg
|
||
|
Ab00102-36.0
|
|
WB
|
Unconjugated
|
4-4-20 (enhanced)
|
200 µg
|
||
|
Ab00102-35.0
|
|
WB
|
Unconjugated
|
4-4-20 (enhanced)
|
200 µg
|
||
|
Ab00102-35.0-BT
|
|
WB
|
Unconjugated
|
4-4-20 (enhanced)
|
1 mg
|
||
|
Ab00102-26.0
|
|
WB
|
Unconjugated
|
4-4-20 (enhanced)
|
200 µg
|
||
|
Ab00102-26.0-BT
|
|
WB
|
Unconjugated
|
4-4-20 (enhanced)
|
1 mg
|
||
|
Ab00102-37.0-BT
|
|
WB
|
Unconjugated
|
4-4-20 (enhanced)
|
1 mg
|
||
|
Ab00102-37.0
|
|
WB
|
Unconjugated
|
4-4-20 (enhanced)
|
200 µg
|
||
|
Ab01102-26.0
|
virus
|
ELISA, Neutralization, WB
|
Unconjugated
|
37.7H
|
200 µg
|
||
|
Ab01102-35.0-BT
|
virus
|
ELISA, Neutralization, WB
|
Unconjugated
|
37.7H
|
1 mg
|
||
|
Ab01102-26.0-BT
|
virus
|
ELISA, Neutralization, WB
|
Unconjugated
|
37.7H
|
1 mg
|
||
|
Ab01102-35.0
|
virus
|
ELISA, Neutralization, WB
|
Unconjugated
|
37.7H
|
200 µg
|
||
|
154-37168
|
|
ELISA, FC, IHC
|
|
4D5-8 (trastuzumab)
|
200 µg
|
||
|
154-32187
|
|
ELISA, WB
|
|
RMH01
|
100 µg
|
||
|
154-37163
|
|
FC
|
|
7E3 (Abciximab)
|
200 µg
|
||
|
154-37155
|
|
FC
|
|
hu1124 (Efalizumab)
|
200 µg
|
||
|
154-37154
|
|
ELISA, FC, IF, IHC
|
|
M200 (Volociximab)
|
200 µg
|
||
|
154-37171
|
|
ELISA
|
|
rhPM-1 (Tocilizumab)
|
200 µg
|
||
|
154-37173
|
|
ELISA
|
|
RSHZ19 (Felvizumab)
|
200 µg
|
||
|
154-30832-50
|
|
ELISA
|
|
D005
|
50 µl
|
||
|
154-37178
|
|
ELISA
|
|
CDP 571 (Humicade)
|
200 µg
|
||
|
154-37180
|
|
ELISA, IF, IHC
|
|
D2E7 (Adalimumab)
|
200 µg
|
||
|
154-37174
|
|
ELISA, FC
|
|
cA2 (Infliximab)
|
200 µg
|
||
|
154-37177
|
|
ELISA
|
|
CDP 571 (Humicade)
|
200 µg
|
||
|
154-37181
|
|
ELISA, IF, IHC
|
|
D2E7 (Adalimumab)
|
200 µg
|
||
|
154-37175
|
|
ELISA, FC
|
|
cA2 (Infliximab)
|
200 µg
|
||
|
154-37179
|
|
ELISA
|
|
CDP 571 (Humicade)
|
200 µg
|
||
|
154-37182
|
|
ELISA, IF, IHC
|
|
D2E7 (Adalimumab)
|
200 µg
|
||
|
154-37176
|
|
ELISA, FC
|
|
cA2 (Infliximab)
|
200 µg
|
||
|
154-37172
|
|
FC
|
|
R4930 (Oxelumab)
|
200 µg
|